CL2009000876A1 - Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno. - Google Patents

Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.

Info

Publication number
CL2009000876A1
CL2009000876A1 CL2009000876A CL2009000876A CL2009000876A1 CL 2009000876 A1 CL2009000876 A1 CL 2009000876A1 CL 2009000876 A CL2009000876 A CL 2009000876A CL 2009000876 A CL2009000876 A CL 2009000876A CL 2009000876 A1 CL2009000876 A1 CL 2009000876A1
Authority
CL
Chile
Prior art keywords
disorders
emesis
anxiety
depression
post
Prior art date
Application number
CL2009000876A
Other languages
English (en)
Inventor
Stefania Beato
Franco Sartor
Ian Philip Steeples
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2009000876A1 publication Critical patent/CL2009000876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

Forma cristalina de maleato de orvepitant anhidro; composición farmacéutica; y uso para preparar un medicamento útil para el tratamiento o profilaxis de trastornos del sistema nervioso central, tales como depresión, ansiedad, trastornos de estrés postrumático, emesis y/o trastornos del sueño.
CL2009000876A 2008-04-11 2009-04-09 Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno. CL2009000876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate

Publications (1)

Publication Number Publication Date
CL2009000876A1 true CL2009000876A1 (es) 2010-05-14

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000876A CL2009000876A1 (es) 2008-04-11 2009-04-09 Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.

Country Status (27)

Country Link
US (1) US8309553B2 (es)
EP (1) EP2297152B1 (es)
JP (2) JP5875863B2 (es)
KR (1) KR20110002090A (es)
CN (1) CN102066376B (es)
AR (1) AR071311A1 (es)
AU (1) AU2009235440B2 (es)
BR (1) BRPI0911678B8 (es)
CA (1) CA2721119C (es)
CL (1) CL2009000876A1 (es)
CY (1) CY1115961T1 (es)
DK (1) DK2297152T3 (es)
EA (1) EA017082B1 (es)
ES (1) ES2529295T3 (es)
GB (1) GB0806652D0 (es)
HR (1) HRP20141196T1 (es)
IL (1) IL208597A0 (es)
MX (1) MX2010011152A (es)
PE (1) PE20091839A1 (es)
PL (1) PL2297152T3 (es)
PT (1) PT2297152E (es)
RS (1) RS53732B1 (es)
SI (1) SI2297152T1 (es)
TW (1) TW201002714A (es)
UY (1) UY31758A (es)
WO (1) WO2009124996A1 (es)
ZA (1) ZA201007120B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842133B (zh) * 2007-10-30 2013-03-20 伊利克塔股份有限公司 放射治疗仪
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
EA201590364A1 (ru) 2012-10-11 2015-11-30 Нерр Терапьютикс Лимитед Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
SI3377064T1 (sl) * 2016-01-08 2019-11-29 Nerre Therapeutics Ltd Orvepitant za zdravljenje kroničnega kašlja
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
IL271464B2 (en) 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression
EP3668876B1 (en) 2017-08-18 2024-01-24 Cothera Bioscience, Inc. Polymorphic form of tg02
AU2021246889A1 (en) * 2020-04-03 2022-10-13 Nerre Therapeutics Limited An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
AU2007253704A1 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
CN101918746A (zh) * 2007-11-02 2010-12-15 诚实公司 无o形圈密封联接件
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
CA2721119A1 (en) 2009-10-15
ES2529295T3 (es) 2015-02-18
BRPI0911678B8 (pt) 2021-05-25
AR071311A1 (es) 2010-06-09
AU2009235440A1 (en) 2009-10-15
PE20091839A1 (es) 2010-01-07
IL208597A0 (en) 2010-12-30
CY1115961T1 (el) 2017-01-25
CN102066376A (zh) 2011-05-18
MX2010011152A (es) 2010-12-21
BRPI0911678B1 (pt) 2021-03-02
KR20110002090A (ko) 2011-01-06
SI2297152T1 (sl) 2015-02-27
RS53732B1 (sr) 2015-06-30
TW201002714A (en) 2010-01-16
JP2014205688A (ja) 2014-10-30
PL2297152T3 (pl) 2015-04-30
CN102066376B (zh) 2014-01-01
JP5875863B2 (ja) 2016-03-02
BRPI0911678A2 (pt) 2015-10-13
EP2297152A1 (en) 2011-03-23
CA2721119C (en) 2016-04-05
EA017082B1 (ru) 2012-09-28
UY31758A (es) 2009-11-10
US20110166150A1 (en) 2011-07-07
JP2011516532A (ja) 2011-05-26
AU2009235440B2 (en) 2012-06-14
GB0806652D0 (en) 2008-05-14
EP2297152B1 (en) 2014-11-12
HRP20141196T1 (hr) 2015-02-13
DK2297152T3 (da) 2015-01-26
PT2297152E (pt) 2015-02-16
US8309553B2 (en) 2012-11-13
EA201071183A1 (ru) 2011-06-30
ZA201007120B (en) 2011-11-30
WO2009124996A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
ECSP14030098A (es) Formas cristalinas de un modulador del receptor androgénico
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
ECSP11011163A (es) Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
IN2014DN09434A (es)
MY157429A (en) Trpm8 antagonists and their use in treatments
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
NI201000214A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4.
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
CO6470823A2 (es) Piperidinas sustituidas
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
CL2012002541A1 (es) Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.
CL2011000184A1 (es) Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos.